6 Overstated
Dietary fiber is the nutrient responsible for maintaining gut function.
"Did you know your gut controls your energy, your recovery, how well you absorb everything that you eat, and the one nutrient that keeps it all running properly is fiber?" (said at 0:24:02)
Dietary fiber plays a well-established and essential role in maintaining gastrointestinal health, regulating transit time, supporting stool formation, and feeding commensal gut microbiota that produce beneficial short-chain fatty acids. However, claiming that fiber is 'the one nutrient' that keeps gut function running properly is an overstatement. Optimal gut function, mucosal barrier integrity, epithelial turnover, and nutrient absorption depend on a wide array of macro- and micronutrients, including amino acids (such as glutamine), essential fatty acids, zinc, and vitamins, alongside adequate hydration.
Clinical trials on AG1 NextGen demonstrated that it fills common nutrient gaps and improves key nutrient levels within 3 months.
"backed by four clinical trials. And in those trials, it was shown to fill common nutrient gaps, improve key nutrient levels in just 3 months" (said at 0:58:47)
Published randomized clinical trials on AG1 have evaluated nutrient absorption and adequacy, but the evidence is more limited in sample size and duration than claimed. A double-blind, randomized crossover trial in 20 resistance-trained adults found that 14 days of AG1 supplementation improved dietary micronutrient adequacy by increasing the number of Estimated Average Requirements (EARs) met, most notably for vitamins A, C, and E. Additionally, a pharmacokinetic crossover trial in 16 adults demonstrated acute absorption (over 8 hours) for multiple vitamins and minerals. However, published trials are short-term (hours to 2–4 weeks) with very small sample sizes (n = 16–30), rather than large 3-month trials establishing clinical reversal of nutrient deficiencies.
Clinical trials on AG1 NextGen showed it increases healthy gut bacteria by 10 times, even in people who already eat well.
"and increase healthy gut bacteria by 10 times, even in people who already eat well." (said at 0:58:57)
A randomized, double-blind, placebo-controlled crossover trial evaluated the effects of 14 days of AG1 supplementation on gut microbiota in 20 healthy, resistance-trained adults. The study found that AG1 did not produce large global shifts in overall microbial alpha or beta diversity, though it was associated with selective enrichment of specific probiotic taxa (such as Lactiplantibacillus plantarum, Lacticaseibacillus rhamnosus, and Bifidobacterium animalis). While marketing statements have extrapolated substantial fold-increases in specific probiotic strains from preliminary or in vitro model data, clinical trials in humans do not demonstrate a generalized 10-fold increase across healthy gut bacteria.
AG1 NextGen is backed by four clinical trials.
"And now they've taken it a step further with AG1 NextGen, backed by four clinical trials." (said at 0:58:47)
The claim that AG1 NextGen is backed by four clinical trials overstates the existing published clinical trial evidence for the product. Published peer-reviewed literature documents three clinical trials evaluating AG1 (PMID: 42518997, PMID: 41988471, PMID: 39352252). A fourth published study evaluating AG1's effects on age-related mobility was conducted in *C. elegans* roundworms, not humans (PMID: 42365207). While human clinical trials demonstrate absorption of vitamins and minerals (PMID: 42518997), improved nutrient adequacy, and selective enrichment of specific probiotic gut taxa (PMID: 41988471, PMID: 39352252), describing all supporting research as four clinical trials overstates the number of human trials present in the published record.
- supports: The effects of AG1® supplementation on the gut microbiome of healthy adults: a random… (Journal of the International Society of Sports Nutrition 2024) · cited 5x in the literature
"Using a double-blind, randomized, two-arm, placebo-controlled, parallel design, we examined a 4-week daily supplementation regimen of AG1 ® vs. placebo (PL)." (abstract, methods)
pubmedfull study (doi) - supports: Effect of AG1 ® supplementation on nutritional adequacy and gut microbial composition… (Frontiers in nutrition 2026)
"This randomized, double-blind, placebo-controlled crossover study examined the effects of two weeks of the nutritional supplement (AG1 ® ) on gut microbial composition, nutritional adequacy, and tolerability." (abstract, methods)
pubmedfull study (doi) - contradicts: A multi-ingredient food supplement slows age-dependent decline of mobility and influences … (Biogerontology 2026)
"We therefore employed C. elegans as a rapidly ageing model organism to investigate the effects of two commercially available nutrition-based products on ageing-related decline of mobility as an indication of healthspan." (abstract, background)
pubmedfull study (doi) - supports: Absorption kinetics of vitamins and minerals from a novel nutritional product in physicall… (Frontiers in nutrition 2026)
"In a randomized, double-blind, placebo-controlled crossover trial 16 healthy adults (8 males and 8 females) consumed a single serving (13 g) of AG1 or a taste- and appearance-matched placebo mixed in water, following a 10-h overnight fast." (abstract, methods)
pubmedfull study (doi)
BPC-157 aids in tissue recovery and gut health.
"Anyway, BPC-157, TB-500, Thymosin Alpha, and SS-31. So, recovery and gut" (said at 1:39:48)
The host's statement implies that BPC-157 is an established therapeutic agent for tissue recovery and gut health. While preclinical animal models and in vitro studies show that BPC-157 promotes angiogenesis, collagen synthesis, and mucosal healing across gastrointestinal and musculoskeletal tissues, robust human clinical trial evidence proving efficacy and safety in humans is lacking. Human data remain restricted to small pilot or exploratory studies, and major regulatory bodies have not approved BPC-157 for clinical use. Therefore, claiming it aids tissue recovery and gut health overstates the current state of scientific evidence.
- supports: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. (Frontiers in pharmacology 2021) · cited 46x in the literature
"By simultaneously curing cutaneous and other tissue wounds (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, and rectovaginal) in rats, the potency of BPC 157 is evident." (abstract, passage verified)
pubmedfull study (doi) - context: From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. (International journal of molecular sciences 2026) · cited 2x in the literature
"BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue... Although animal data indicate favorable safety and pharmacokinetics, human research remains limited to small pilot studies investigating musculoskeletal pain, interstitial cystitis, and intravenous administration" (abstract, passage verified)
pubmedfull study (doi)
TB-500 promotes tissue recovery and bone regeneration.
"TB-500, Thymosin Alpha, and SS-31. So, recovery and gut; more recovery because I had a tooth extraction a little while ago and I'm trying to regrow a bone in my face" (said at 1:39:48)
Preclinical in vitro and rodent studies indicate that thymosin beta-4 (and its synthetic derivative TB-500) has regenerative properties that can facilitate angiogenesis, wound healing, and fracture repair. However, these effects have not been demonstrated in clinical trials for bone regeneration or post-extraction healing in humans. A comprehensive review of emerging peptides in musculoskeletal medicine concluded that the claimed benefits of TB-500 remain unsubstantiated by clinical trials.
9 Supported by research
Approximately 1 in 5,000 people rupture their Achilles tendon.
"I think one in 5,000 people rupture their Achilles." (said at 0:07:40)
An incidence of 1 in 5,000 individuals corresponds to an annual incidence rate of 20 per 100,000 person-years (0.02% per year). A comprehensive systematic review and meta-analysis of 28 population-based registry studies covering over 630 million person-years found a pooled global incidence of 15.7 per 100,000 person-years, with modern rates ranging from approximately 18 to 32 per 100,000 person-years depending on the region and year. Thus, the stated figure accurately reflects the annual population incidence of acute Achilles tendon ruptures.
- supports: The epidemiology and trends in management of acute Achilles tendon ruptures in Ontario, Ca… (The bone & joint journal 2017) · cited 140x in the literature
"A total of 27 607 patients (median age, 44 years; interquartile range 26 to 62; 66.5% male) sustained an AATR. The annual IDR increased from 18.0 to 29.3 per 100 000 person-years between 2003 and 2013." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Incidence, Temporal Trends, and Surgical Shift of Achilles Tendon Rupture: A Systematic Re… (Sports medicine (Auckland, N.Z.) 2026) · cited 4x in the literature
"Twenty-eight studies reporting Achilles tendon ruptures from 1950 to 2022 were included, representing over 630 million individuals and 568,000 Achilles tendon rupture cases. The pooled global incidence was 15.7 per 100,000 person-years, spanning from 6.1 in 1979 to 31.1 per 100,000 person-years in 2021, with an average annual increase of 2.7% (95% confidence interval 2.0-3.3%)." (abstract, results, passage verified)
pubmedfull study (doi)
95% of Americans do not consume enough dietary fiber.
"Well, it turns out that 95% of Americans don't get enough of it" (said at 0:24:10)
Nationally representative dietary data in the United States (such as from the National Health and Nutrition Examination Survey, NHANES) consistently demonstrate that only approximately 5% of the population meets the recommended Adequate Intake for dietary fiber, meaning roughly 95% of Americans fail to consume enough fiber.
Platypuses possess venom.
"platypuses are like freak alien otters. Also cute but have weird venom." (said at 0:41:45)
Male platypuses (Ornithorhynchus anatinus) possess a specialized crural venom system consisting of crural glands in the upper thigh connected via ducts to calcaneus spurs on their hind limbs. The venom contains a complex cocktail of unique proteins and peptides, including defensin-like peptides, C-type natriuretic peptides, and other novel toxins that are primarily produced seasonally during the breeding season.
Platypuses lay eggs.
"They also lay eggs, but they're kind of mammally as well." (said at 0:41:51)
The platypus (Ornithorhynchus anatinus) is a monotreme, an order of extant mammals that reproduce by laying eggs (oviparous reproduction) while possessing mammalian traits such as lactation and fur.
One scoop of AG1 contains 75 vitamins, minerals, probiotics, and whole-food sourced ingredients.
"One scoop contains 75 vitamins, minerals, probiotics, and whole-food sourced ingredients in a single daily drink." (said at 0:58:44)
The statement accurately reflects the formulation of AG1 (Athletic Greens), a commercial dietary supplement formulated as a single daily powdered drink combining 75 ingredients categorized across vitamins, minerals, probiotics, and whole-food sourced phytonutrient complexes. Published clinical trials investigating the supplement confirm its composition as a multi-ingredient formulation containing vitamins, minerals, probiotics, and plant-derived phytochemicals.
- supports: Effect of AG1 ® supplementation on nutritional adequacy and gut microbial composition… (Frontiers in nutrition 2026)
"Dietary supplements that combine vitamins, minerals, phytonutrients, prebiotics, and probiotics have gained popularity among health-oriented consumers seeking convenient ways to fill nutritional gaps and support gut health." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Absorption kinetics of vitamins and minerals from a novel nutritional product in physicall… (Frontiers in nutrition 2026)
"This clinical trial assessed the acute absorption phase of key micronutrients in AG1, a comprehensive nutritional supplement containing vitamins, minerals, probiotics, and phytochemicals." (abstract, results, passage verified)
pubmedfull study (doi)
Breath tests for SIBO can determine whether the overgrowth is hydrogen-based or methane-based.
"You'll get your breath test back. It'll tell you whether it's whatever it is, fucking hydrogen-based or methane-based or whatever, and then just go through the standard process." (said at 1:23:24)
Breath testing for small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) measures exhaled concentrations of both hydrogen (H2) and methane (CH4) following the ingestion of a carbohydrate substrate such as glucose or lactulose. According to the North American Consensus guidelines for breath testing in gastrointestinal disorders, a rise in hydrogen of ≥20 ppm by 90 minutes defines a hydrogen-positive test, whereas a methane concentration of ≥10 ppm at any point during testing defines a methane-positive test.
SIBO is typically treated using an antibiotic protocol.
"SIBO's relatively easy to treat. I think it's kind of linear... follow the doctor's advice, do the antibiotics, and then see how you are on the other side of it." (said at 1:23:34)
Clinical guidelines and systematic reviews confirm that antibiotic therapy (most commonly the nonabsorbable antibiotic rifaximin) is the standard and primary approach to treating small intestinal bacterial overgrowth (SIBO). Meta-analyses of clinical trials demonstrate that antibiotic protocols achieve significantly higher breath test normalization and symptom improvement compared with placebo, although clinical practice guidelines note that addressing underlying causes is also necessary due to risk of recurrence.
Thymosin alpha-1 provides immune system support.
"immune support with the Thymosin Alpha" (said at 1:40:05)
Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland that functions as an immunomodulatory agent. A substantial body of preclinical and clinical literature, including randomized controlled trials and systematic reviews, demonstrates that thymosin alpha-1 modulates immune function by stimulating T-cell differentiation, enhancing antigen presentation, regulating lymphocyte subsets (such as CD4+ and CD8+ T cells), and balancing inflammatory cytokine production across various clinical contexts, including severe infections, sepsis, and liver disease.
- supports: The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic r… (BMC infectious diseases 2016) · cited 52x in the literature
"As to the immunological indicators, the level of HLA-DR were increased by Tα1 (SMD 1.23, 95 % CI 0.28 to 2.18, p = 0.01) according to the pooled analysis of 8 studies involving 721 patients. Lymphocyte subsets CD3, CD4 and cytokines IL-6, IL-10 and TNF-α were also beneficially affected by Tα1 treatment." (abstract, results)
pubmedfull study (doi) - supports: Aging and Thymosin Alpha-1. (International journal of molecular sciences 2025)
"Thymosin alpha-1 (Tα1), a peptide hormone produced by the thymus, exhibits potent immunomodulatory, anti-inflammatory, and antioxidant properties. It helps restore immune function by stimulating T-cell differentiation, enhancing thymic output, and modulating dendritic cell and macrophage activity." (abstract)
pubmedfull study (doi)
SS-31 (elamipretide) provides mitochondrial support.
"and then mitochondrial support with the SS-31 because I'm tired all the time." (said at 1:40:08)
SS-31 (also known as elamipretide, MTP-131, or Bendavia) is a mitochondria-targeted tetrapeptide specifically developed to support mitochondrial function. It selectively binds to cardiolipin on the inner mitochondrial membrane, stabilizing cristae architecture, optimizing electron transport chain efficiency, promoting adenosine triphosphate (ATP) synthesis, and decreasing excessive reactive oxygen species production across extensive preclinical and clinical studies.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.